{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:53:55Z","timestamp":1793404435077,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejso.2025.110534","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:06:44Z","timestamp":1761059204000},"page":"110534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety of high-dose mitomycin C vs oxaliplatin HIPEC for peritoneal metastases"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9100-7053","authenticated-orcid":false,"given":"Giancarlo","family":"Sticca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-5774","authenticated-orcid":false,"given":"Mikael","family":"Soucisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Abou-Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai-Kim","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Sideris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2025.110534_bib1","unstructured":"Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures Surgery | JAMA Network Open | JAMA Network. Accessed: February. 10, 2025. [Online]. Available: https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2720582."},{"issue":"2","key":"10.1016\/j.ejso.2025.110534_bib2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1245\/s10434-024-16441-z","article-title":"Ten-year outcome of a randomized trial: cytoreduction and HIPEC with Mitomycin C versus oxaliplatin for appendiceal neoplasm with peritoneal dissemination","volume":"32","author":"Levine","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"10 Pt A","key":"10.1016\/j.ejso.2025.110534_bib3","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.ejso.2020.04.018","article-title":"Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study","volume":"46","author":"Bakkers","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2025.110534_bib4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4251\/wjgo.v12.i8.903","article-title":"Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer","volume":"12","author":"Spiegelberg","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.ejso.2025.110534_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.critrevonc.2019.06.014","article-title":"Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer","volume":"142","author":"Wisselink","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1016\/j.ejso.2025.110534_bib6","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00384-020-03702-y","article-title":"Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies","volume":"35","author":"Zhang","year":"2020","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"10.1016\/j.ejso.2025.110534_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2025.110534_bib8","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study","volume":"21","author":"Go\u00e9r\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2025.110534_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ejso.2025.110534_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.21614\/chirurgia.2708","article-title":"Hyperthermic intraperitoneal chemotherapy with Mitomycin C versus Oxaliplatin after cytoreductive surgery for the treatment of peritoneal metastases of colorectal cancer origin","volume":"117","author":"Papageorgopoulou","year":"2022","journal-title":"Chirurgia (Bucur)"},{"issue":"2","key":"10.1016\/j.ejso.2025.110534_bib11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejso.2017.10.216","article-title":"Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC","volume":"44","author":"van Eden","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ejso.2025.110534_bib12","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1245\/s10434-015-4679-9","article-title":"Mitomycin C pharmacokinetics as predictor of severe neutropenia in hyperthermic intraperitoneal therapy","volume":"22","author":"Kemmel","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.110534_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1245\/s10434-023-14368-5","article-title":"2022 peritoneal surface oncology group international consensus on HIPEC regimens for peritoneal malignancies: colorectal cancer","volume":"31","author":"H\u00fcbner","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.110534_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/02656736.2017.1345014","article-title":"Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"34","author":"Tan","year":"2018","journal-title":"Int J Hyperther"},{"issue":"4 Pt A","key":"10.1016\/j.ejso.2025.110534_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ejso.2019.10.032","article-title":"Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies","volume":"46","author":"Somashekhar","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.110534_bib16","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.1503\/cjs.001619","article-title":"Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study","volume":"64","author":"Benzaquen","year":"2021","journal-title":"Can J Surg"},{"issue":"7","key":"10.1016\/j.ejso.2025.110534_bib17","first-page":"293","article-title":"Neutropenic enterocolitis: a continuing medical and surgical challenge","volume":"2","author":"Machado","year":"2010","journal-title":"N Am J Med Sci"},{"issue":"8","key":"10.1016\/j.ejso.2025.110534_bib18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1245\/s10434-009-0523-4","article-title":"Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C","volume":"16","author":"Lambert","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.110534_bib19","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1245\/s10434-021-10924-z","article-title":"Impact of Mitomycin-C-Induced neutropenia after hyperthermic intraperitoneal chemotherapy with cytoreductive surgery in colorectal cancer patients with peritoneal carcinomatosis","volume":"29","author":"Lee","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.110534_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejso.2021.08.027","article-title":"The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy","volume":"48","author":"Verwaal","year":"2022","journal-title":"Eur J Surg Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2025.110534_bib21","doi-asserted-by":"crossref","first-page":"8583","DOI":"10.1245\/s10434-022-12358-7","article-title":"Pharmacologic effects of oxaliplatin instability in chloride-containing carrier fluids on the hyperthermic intraperitoneal chemotherapy to treat colorectal cancer in vitro and in vivo","volume":"29","author":"Park","year":"2022","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832500962X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832500962X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T23:56:30Z","timestamp":1764028590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879832500962X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S074879832500962X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110534","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of high-dose mitomycin C vs oxaliplatin HIPEC for peritoneal metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110534"}}